We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed yesterday at ...

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...

GSK reiterated its full-year guidance after its new HIV and cancer treatments lifted profit ahead of analysts’ expectations ...

Wednesday, GSK Plc (NYSE:GSK) reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% ...

Diabetes Singapore and GSK aim to enhance awareness and improve lives affected by diabetes through educational talks and activities on World Diabetes Day; 1 in 3 people will get s ...

GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.